Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

ITC reported for 2023 by RAS

3/11/24 WTCM

ICPAO Yandex applied to the Moscow Exchange for listing

3/11/24 YNDX

Shareholders of Rosgosstrakh approved dividends

3/11/24 RGSS

SberMarket launched furniture delivery

3/11/24 SBER

VOX raised ₽9.6 million in investment

3/11/24 OTCI

En+ Group completed the first stage of modernization of the Irkutsk HPP

3/11/24 ENPG

RusHydro started designing Tolmachevskaya HPP-4

3/11/24 HYDR

Henderson sales in February were up 37%

3/11/24 HNFG

Government has selected an operator for the exchange of blocked assets

3/11/24 MOEX

Rostelecom became an IP-telephony operator Mango Telecom

3/11/24 RTKM